Beth Y. Karlan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beth Y. Karlan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Rae Lynn Baldwin
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California, 90048
3 shared publicationsDennis Slamon
Department of Medicine, University of California, Los Angeles, California, 90095
2 shared publicationsJohn C. Elkas
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California, 90048
2 shared publicationsMark Pegram
Department of Medicine, University of California, Los Angeles, California, 90095
2 shared publicationsYiou Tseng
Department of Medicine, University of California, Los Angeles, California, 90095
2 shared publications- Andrea Eisen
Toronto-Sunnybrook Regional Cancer Center, Toronto, Canada
1 shared publication
Latest Publications
- 1 May 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 149 (2) , 227-229
Sexual harassment in the work place: Its impact on gynecologic oncology and women's health
- 1 May 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 149 (2) , 227-229
Sexual harassment in the work place: Its impact on gynecologic oncology and women's health
- 1 January 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (1) , 1-2
Gynecologic Oncology 2017 Update: New Features and Expanded Scope
- 1 January 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (1) , 1-2
Gynecologic Oncology 2017 Update: New Features and Expanded Scope
- 1 July 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (1) , 155-167
The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice
Genetic counseling and testing for inherited disorders are part of every obstetrician-gynecologist's practice. Family history, ethnicity, and race are routinely evaluated as a part of the prenatal assessment. The discovery of genes responsible for inherited cancer susceptibility and the wide availability of clinical genetic testing for mutations in these genes have made similar assessments an integral part of gynecologic practice as well. The indications for genetic testing for mutations in BRCA1, BRCA2, and the mismatch repair genes responsible for the hereditary nonpolyposis colon cancer (HNPCC) syndrome need to be individualized. As in obstetrics, genetic counseling can provide critical assessment of the family history to help determine the likelihood of an inherited cancer susceptibility syndrome and the appropriateness of genetic testing. The subsequent clinical recommendations for mutation carriers need to take into account the patient's age, desire for future childbearing, and other medical history when prescribing screening interventions or prophylactic surgery. Practical applications of genetic testing for cancer susceptibility have the ability to reduce the burden of hereditary cancers by saving lives, decreasing medical morbidities, and reducing psychological stress.
- 1 July 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (1) , 155-167
The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice
Genetic counseling and testing for inherited disorders are part of every obstetrician-gynecologist's practice. Family history, ethnicity, and race are routinely evaluated as a part of the prenatal assessment. The discovery of genes responsible for inherited cancer susceptibility and the wide availability of clinical genetic testing for mutations in these genes have made similar assessments an integral part of gynecologic practice as well. The indications for genetic testing for mutations in BRCA1, BRCA2, and the mismatch repair genes responsible for the hereditary nonpolyposis colon cancer (HNPCC) syndrome need to be individualized. As in obstetrics, genetic counseling can provide critical assessment of the family history to help determine the likelihood of an inherited cancer susceptibility syndrome and the appropriateness of genetic testing. The subsequent clinical recommendations for mutation carriers need to take into account the patient's age, desire for future childbearing, and other medical history when prescribing screening interventions or prophylactic surgery. Practical applications of genetic testing for cancer susceptibility have the ability to reduce the burden of hereditary cancers by saving lives, decreasing medical morbidities, and reducing psychological stress.
- Open Access
- 21 March 2006
- Published by Springer Nature in Breast Cancer Research
- Vol. 8 (2) , 1-7
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers
Introduction: BRCA1 and BRCA2 mutation carriers are at increased risk for developing both breast and ovarian cancer. It has been suggested that carriers of BRCA1/2 mutations may also be at increased risk of having recurrent (three or more) miscarriages. Several reproductive factors have been shown to influence the risk of breast cancer in mutation carriers, but the effects of spontaneous and therapeutic abortions on the risk of hereditary breast cancer risk have not been well studied to date. Methods: In a matched case-control study, the frequencies of spontaneous abortions were compared among 1,878 BRCA1 mutation carriers, 950 BRCA2 mutation carriers and 657 related non-carrier controls. The rates of spontaneous and therapeutic abortions were compared for carriers with and without breast cancer. Results: There was no difference in the rate of spontaneous abortions between carriers of BRCA1 or BRCA2 mutations and non-carriers. The number of spontaneous abortions was not associated with breast cancer risk among BRCA1 or BRCA2 mutation carriers. However, BRCA2 carriers who had two or more therapeutic abortions faced a 64% decrease in the risk of breast cancer (odds ratio = 0.36; 95% confidence interval 0.16–0.83; p = 0.02). Conclusion: Carrying a BRCA1 or BRCA2 mutation is not a risk factor for spontaneous abortions and spontaneous abortions do not appear to influence the risk of breast cancer in carriers of BRCA1 or BRCA2 mutations. However, having two or more therapeutic abortions may be associated with a lowered risk of breast cancer among BRCA2 carriers.
- 21 March 2006
- Published by Springer Nature in Breast Cancer Research
- Vol. 8 (2) , 1-7
Open AccessSpontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers
Introduction: BRCA1 and BRCA2 mutation carriers are at increased risk for developing both breast and ovarian cancer. It has been suggested that carriers of BRCA1/2 mutations may also be at increased risk of having recurrent (three or more) miscarriages. Several reproductive factors have been shown to influence the risk of breast cancer in mutation carriers, but the effects of spontaneous and therapeutic abortions on the risk of hereditary breast cancer risk have not been well studied to date. Methods: In a matched case-control study, the frequencies of spontaneous abortions were compared among 1,878 BRCA1 mutation carriers, 950 BRCA2 mutation carriers and 657 related non-carrier controls. The rates of spontaneous and therapeutic abortions were compared for carriers with and without breast cancer. Results: There was no difference in the rate of spontaneous abortions between carriers of BRCA1 or BRCA2 mutations and non-carriers. The number of spontaneous abortions was not associated with breast cancer risk among BRCA1 or BRCA2 mutation carriers. However, BRCA2 carriers who had two or more therapeutic abortions faced a 64% decrease in the risk of breast cancer (odds ratio = 0.36; 95% confidence interval 0.16–0.83; p = 0.02). Conclusion: Carrying a BRCA1 or BRCA2 mutation is not a risk factor for spontaneous abortions and spontaneous abortions do not appear to influence the risk of breast cancer in carriers of BRCA1 or BRCA2 mutations. However, having two or more therapeutic abortions may be associated with a lowered risk of breast cancer among BRCA2 carriers.
- 1 November 2002
- Published by Elsevier in Gynecologic Oncology
- Vol. 87 (2) , 200-206
A Human Ovarian Carcinoma Murine Xenograft Model Useful for Preclinical Trials
- 1 November 2002
- Published by Elsevier in Gynecologic Oncology
- Vol. 87 (2) , 200-206
A Human Ovarian Carcinoma Murine Xenograft Model Useful for Preclinical Trials
- 17 October 2002
- Published by Elsevier in Gynecologic Oncology
- Vol. 87 (2) , 200-206
A Human Ovarian Carcinoma Murine Xenograft Model Useful for Preclinical Trials
- 17 October 2002
- Published by Elsevier in Gynecologic Oncology
- Vol. 87 (2) , 200-206
A Human Ovarian Carcinoma Murine Xenograft Model Useful for Preclinical Trials
- 1 August 1999
- Published by Elsevier in Gynecologic Oncology
- Vol. 74 (2) , 265-271
Primary Ovarian Cancer Cultures are Resistant to Fas-Mediated Apoptosis
- 1 August 1999
- Published by Elsevier in Gynecologic Oncology
- Vol. 74 (2) , 265-271
Primary Ovarian Cancer Cultures are Resistant to Fas-Mediated Apoptosis